PRECISION BIOSCIENCES INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
PRECISION BIOSCIENCES INC (DTIL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -9.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-12
- PRECISION BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -9.50%, a 131.77% decline from fiscal 2024.
- PRECISION BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 29.90%.
- PRECISION BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -1.20%.
- PRECISION BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -0.50%, a 107.35% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -9.50% 10-K · filed 2026-03-12 | |
| 2024-12-31 | 29.90% 10-K · filed 2026-03-12 | 14.40% 10-K · filed 2025-03-26 |
| 2023-12-31 | -1.20% 10-K · filed 2025-03-26 | |
| 2022-12-31 | -0.50% 10-K · filed 2024-03-27 | |
| 2021-12-31 | 6.80% 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |